Pharmaceutical industry – Page 39
-
BusinessClinical trial death highlights hazards
Pain drug trial has left one dead and five hospitalised in France, with little indication as to the cause of the problems
-
BusinessGSK scientists indicted for trade secret theft
Two researchers accused of passing research data and manufacturing details to Chinese firm
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
-
-
Business
BioAtla and Pfizer to collaborate on antibody research
Two-way agreement to share technology and royalties on new cancer drugs
-
Business
Mexico approves world’s first dengue vaccine
Sanofi’s vaccine protects children and adults against the mosquito-borne disease
-
-
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Perrigo nabs US rights to AZ Crohn’s drug
Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio
-
Business
Pfizer to close Cambridge pain outpost
120 jobs under threat from closure of Neusentis subsidiary R&D site
-
NewsPfizer’s response to compound fraud spotlights quality issues
‘Bosutinib isomer’ typifies threat posed by evolution of chemical supply chain
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Business
Drug firms to share chemical compound libraries
AstraZeneca and Sanofi aim to facilitate drug discovery by swapping 210,000 proprietary chemical compounds
-
Opinion
Toeing the advertising line
Companies have to tread a little carefully when it comes to advertising prescription drugs
-
BusinessViral cancer therapy approved in the US
T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review